Urocortin modulates dopaminergic neuronal survival via inhibition of glycogen synthase kinase-3β and histone deacetylase

Neurobiology of Aging

Volumn 32, Issue 9, 2011, Pages 1662-1677

  Huang, Hsin Yi ^a,b   Lin, Shinn Zong ^c   Chen, Wu Fu ^d   Li, Kuo Wei ^a   Kuo, Jon Son ^b   Wang, Mei Jen ^a,b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

CAMP; Corticotropin releasing hormone; Dopaminergic neurons; GSK 3 ; HDAC; Neuropeptide; Substantia nigra; Urocortin

Indexed keywords

CASPASE 3; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CYCLIC AMP; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE; HISTONE H3; UROCORTIN;

ANIMAL CELL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EMBRYO; ENZYME INHIBITION; HISTONE ACETYLATION; MOUSE; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; AUTOCRINE COMMUNICATION; CELL DEATH; CELL SURVIVAL; CELLS, CULTURED; CORTICOTROPIN-RELEASING HORMONE; DOPAMINE; GLYCOGEN SYNTHASE KINASE 3; HISTONE DEACETYLASE 1; HUMANS; MICE; NEURONS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; UROCORTINS;

EID: 79960114694     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.09.010     Document Type: Article

References (63)

1. Abuirmeileh A., Harkavyi A., Lever R., Biggs C.S., Whitton P.S. Urocortin, a CRF-like peptide, restores key indicators of damage in the substantia nigra in a neuroinflammatory model of Parkinson's disease. J. Neuroinflammation 2007, 4:19.
2. Abuirmeileh A., Lever R., Kingsbury A.E., Lees A.J., Locke I.C., Knight R.A., Chowdrey H.S., Biggs C.S., Whitton P.S. The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease. Eur. J. Neurosci. 2007, 26:417-423.
3. Agnello D., Bertini R., Sacco S., Meazza C., Villa P., Ghezzi P. Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin. Endocrinol. Metab. 1998, 38:E757-E762.
4. Anglade P., Vyas S., Javoy-Agld F., Herrero M.T., Michel P.P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E.C., Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 1997, 12:25-31.
5. Anglade P., Vyas S., Hirsch E.C., Agid Y. Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol. Histopathol. 1997, 12:603-610.
6. Bayatti N., Behl C. The neuroprotective actions of corticotropin releasing hormone. Ageing Res. Rev. 2005, 4:258-270.
7. Bayatti N., Zschocke J., Behl C. Brain region-specific neuroprotective action and signaling of corticotrophin-releasing hormone in primary neurons. Endocrinology 2003, 144:4051-4060.
8. Bhat R.V., Shanley J., Correll M.P., Fieles W.E., Keith R.A., Scott C.W., Lee C.M. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:11074-11079.
9. Bhat R.V., Budd S.L. GSK3beta signaling: casting a wide net in Alzheimer's disease. Neurosignals 2002, 11:251-261.
10. Chen G., Bower K.A., Ma C., Fang S., Thiele C.J., Luo J. Glycogen synthase kinase 3β (GSK3β) mediates 6-hydroxydopamine-induced neuronal death. FASEB J. 2004, 18:1162-1164.
11. Chen L.-W., Yung K.K.L., Chan Y.S. Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease. Curr. Drug Targets 2004, 5:197-206.
12. Chen P.-S., Peng G.-S., Li G., Yang S., Wu X., Wang C.-C., Wilson B., Lu R.-B., Gean P.-W., Chuang D.-M., Hong J.-S. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol. Psychiatry 2006, 11:1116-1125.
13. Chin P.C., Majdzadeh N., D'Mello S.R. Inhibition of GSK3β is a common event in neuroprotection by different survival factors. Mol. Brain Res. 2005, 137:193-201.
14. Cosio B.G., Tsaprouni L., Ito K., Jazrawi E. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med. 2004, 200:689-695.
15. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
16. Dautzenberg F.M., Kilpatrick G.J., Hauger R.L., Moreau J. Molecular biology of the CRH receptors in the mood. Peptides 2001, 22:753-760.
17. Dawson T.M., Dawson V.L. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat. Neurosci. 2002, 5(Suppl.):1058-1061.
18. Facci L., Stevens D.A., Pangallo M., Franceschini D., Skaper S.D., Strijbos P.J.L.M. Corticotropin-releasing factor (CRF) and related peptides confer neuroprotection via type 1 CRF receptors. Neuropharmacology 2003, 45:623-636.
19. Fernandez A., de Ceballos M.L., Rose S., Jenner P., Marsden C.D. Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease. Brain 1996, 119:823-830.
20. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., Smith K., Kowall N.W., Ratan R.R., Luthi-Carter R., Hersch S.M. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 2003, 23:9418-9427.
21. Grammatopoulos D.K., Randeva H.S., Levine M.A., Kanellopoulou K.A., Hillhouse E.W. Rat cerebral cortex corticotropin-releasing hormone receptors: evidence for receptor coupling to multiple G-proteins. J. Neurochem. 2001, 76:509-519.
22. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase 3beta in cellular signaling. Prog. Neurobiol. 2001, 65:391-426.
23. Hashimoto R., Hough C., Nakazawa T., Yamamoto T., Chuang D.-M. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J. Neurochem. 2002, 80:589-597.
24. Hetman M., Cavanaugh J.E., Kimelman D., Xia Z. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J. Neurosci. 2000, 20:2567-2574.
25. Hiroi T., Wei H., Hough C., Leeds P., Chuang D.-M. Protected lithium treatment protects against the ER stress elicited by thapsigargin in rat PC12 cells: roles of intracellular calcium, GRP78 and Bcl-2. Pharmacogenomics J. 2005, 5:102-111.
26. Ishitani R., Sunaga K., Hirano A., Saunders P., Katsube N., Chuang D.-M. Evidence that glyceraldehydes-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture. J. Neurochem. 1996, 66:928-935.
27. Ishitani R., Kimura M., Sunaga K., Katsube N., Tanaka M., Chuang D.-M. An antisense oligodeoxynucleotide to glyceraldehydes-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. J. Pharmacol. Exp. Ther. 1996, 278:447-454.
28. Ishunina T.A., Swaab D.F. Neurohypophyseal peptides in aging and Alzheimer's disease. Ageing Res. Rev. 2002, 1:537-558.
29. Ito K., Lim S., Caramori G., Cosio B., Fan Chung K., Adcock I.M., Barnes P.J. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:8921-8926.
30. Jeong M.R., Hashimoto R., Senatorov V., Fujimaki K., Ren M., Lee M.S., Chuang D.-M. Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Lett. 2003, 542:74-78.
31. Kanni H., Sawa A., Chen R.W., Leeds P., Chuang D.-M. Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons. Pharmacogenomics J. 2004, 4:336-344.
32. Kaytor M.D., Orr H.T. The GSK3 beta signaling cascade and neurodegenerative disease. Curr. Opin. Neurobiol. 2002, 12:275-278.
33. Kelly S., Zhao H., Hua Sun G., Cheng D., Qiao Y., Luo J., Martin K., Steinberg G.K., Harrison S.D., Yenari M.A. Glycogen synthase kinase 3beta inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemia. Exp. Neurol. 2004, 188:378-386.
34. Kim A.J., Shi Y., Austin R.C., Werstuck G.H. Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J. Cell Sci. 2005, 118:89-99.
35. Koh S.-H., Noh M.Y., Kim S.H. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res. 2008, 1188:254-262.
36. Le Couteur D.G., Muller M., Yang M.C., Mellick G.D., McLean A.J. Age-environment and gene-environment interactions in the pathogenesis of Parkinson's disease. Rev. Environ. Health 2002, 17:51-64.
37. Leng Y., Chuang D.-M. Endogenous α-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J. Neurosci. 2006, 26:7502-7512.
38. Lewis K., Li C., Perrin M.H., Blount A., Kunitake K., Donaldson C., Vaughan J., Reyes T.M., Gulyas J., Fischer W., Bilezikjian L., Rivier J., Sawchenko P.E., Vale W.W. Identification of urocortin III, an additional member of the corticotrophin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:7570-7575.
39. Li M., Wang X., Meintzer M.K., Laessig T., Birnbaum M.J., Heidenreich K.A. Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3β. Mol. Cell. Biol. 2000, 20:9356-9363.
40. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001, 20:27-39.
41. Maggirwar S.B., Tong N., Ramirez S., Gelbard H.A., Dewhurst S. HIV-1 tat-mediated activation of glycogen synthase kinase-3β contributes to tat-mediated neurotoxicity. J. Neurochem. 1999, 73:578-586.
42. Michel P.P., Agid Y. Chronic activation of the cyclic AMP signaling pathway promotes development and long-term survival of mesencephalic dopaminergic neurons. J. Neurochem. 1996, 67:1633-1642.
43. Minamiyama M., Katsuno M., Adachi H., Waza M., Sang C., Kobayashi Y., Tanaka F., Doyu M., Inukai A., Sobue G. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 2004, 13:1183-1192.
44. Oliveira J.M.A., Chen S., Almeida S., Riley R., Goncalves J., Oliveira C.R., Hayden M.R., Nicholls D.G., Ellerby L.M., Rego A.C. Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. J. Neurosci. 2006, 26:11174-11186.
45. Outeiro T.F., Kontopoulos E., Altmann S.M., Kufareva I., Strathearn K.E., Amore A.M., Volk C.B., Maxwell M.M., Rochet J.-C., McLean P.J., Young A.B., Abagyan R., Feany M.B., Hyman B.T., Kazantsev A.G. Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007, 317:516-519.
46. Pan W., Kastin A.J. Urocortin and the brain. Prog. Neurobiol. 2008, 84:148-156.
47. Pedersen W.A., Wan R., Zhang P., Mattson M.P. Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type 1. J. Neurosci. 2002, 22:404-412.
48. Peng G.S., Li G., Tzeng N.S., Chen P.S., Chuang D.-M., Hsu Y.D., Yang S., Hong J.-S. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res. Mol. Brain Res. 2005, 134:162-169.
49. Perrin M.H., Vale W.W. Corticotropin-releasing factor receptors and their ligand family. Ann. N. Y. Acad. Sci. 1999, 885:312-328.
50. Ren M., Leng Y., Jeong M., Leeds P.R., Chuang D.-M. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 2004, 89:1358-1367.
51. Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A., Hogenesch J.B., Gulyas J., Rivier J., Vale W.W., Sawchenko P.E. Urocortin II: a member of the corticotrophin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:2843-2848.
52. Sauvage M., Steckler T. Detection of corticotrophin-releasing hormone receptor 1 immunoreactivity in cholinergic, dopaminergic and noradrenergic neurons of the murine basal forebrain and brainstem nuclei-potential implication for arousal and attention. Neuroscience 2001, 104:643-652.
53. Schapira A.H. Causes of neuronal death in Parkinson's disease. Adv. Neurol. 2001, 86:155-162.
54. Song L., De Sarno P., Jope R.S. Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J. Biol. Chem. 2002, 277:44701-44708.
55. Stevens S.L., Shaw T.E., Dykhuizen E., Lessov N.S., Hill J.K., Wurst W., Stenzel-Poore M.P. Reduced cerebral injury in CRH-R1 deficient mice after focal ischemia: a potential link to microglia and astrocytes that express CRH-R1. J. Cereb. Blood Flow Metab. 2003, 23:1151-1159.
56. Strahl B.D., Allis C.D. The language of covalent histone modification. Nature 2000, 403:41-45.
57. Tong N., Sanchez J.F., Maggirwar S.B., Ramirez S.H., Guo H., Dewhurst S., Gelbard H.A. Activation of glycogen synthase kinase 3 beta (GSK-3β) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. Eur. J. Neurosci. 2001, 13:1913-1922.
58. Tu H., Kastin A.J., Pan W. Corticotropin-releasing hormone receptor (CRHR)1 and CRHR2 are both trafficking and signaling receptors for urocortin. Mol. Endocrinol. 2007, 21:700-711.
59. Tu H., Kastin A.J., Bjorbaek C., Pan W. Urocortin trafficking in cerebral microvessel endothelial cells. J. Mol. Neurosci. 2007, 31:171-181.
60. Van Pett K., Viau V., Bittencourt J.C., Chan R.K., Li H.Y., Arias C., Prins G.S., Perrin M., Vale W., Sawchenko P.E. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J. Comp. Neurol. 2000, 428:191-212.
61. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S., Chan R., Turnbull A.V., Lovejoy D., Rivier C., Rivier J., Sawchenko P.E., Vale W. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995, 378:287-292.
62. Wang M.-J., Lin S.-Z., Kuo J.-S., Huang H.-Y., Tzeng S.-F., Liao C.-H., Chen D.-C., Chen W.-F. Urocortin modulates inflammatory response and neurotoxicity induced by microglial activation. J. Immunol. 2007, 179:6204-6214.
63. Xu J., Culman J., Blume A., Brecht S., Gohlke P. Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death. Stroke 2003, 34:1287-1292.